Oriol Mirallas, Clinical Fellow in the Investigational Cancer Therapeutics (ICT) Department at the University of Texas MD Anderson Cancer Center, shared a post on LinkedIn:
“Pleased to share that our review, ‘Targeting regulatory T cells for cancer immunotherapy: promises and pitfalls,’ is now available in the August issue of Annals of Oncology.
This work discusses the therapeutic opportunities and challenges associated with targeting regulatory T cells in cancer, including their biological complexity, potential biomarkers, and emerging treatment strategies.”
Title: Targeting regulatory T cells for cancer immunotherapy: promises and pitfalls
Authors: O. Mirallas, G. Pretelli, M. Balsa, P. Jiménez-Labaig, A. Hernando-Calvo, H. Nathan Tan, P.N. Selvadurai, P. Tallón de Lara, M. Vieito, J. Martin-Liberal, K.J. Harrington, S. Champiat, E. Garralda
Read The Full Article
